Westside Investment Management Inc. acquired a new stake in shares of Merck & Co., Inc. (NYSE:MRK) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 2,765 shares of the company’s stock, valued at approximately $231,000.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. JJJ Advisors Inc. bought a new stake in shares of Merck & Co., Inc. in the second quarter worth $27,000. PRW Wealth Management LLC bought a new stake in shares of Merck & Co., Inc. in the fourth quarter worth $41,000. Aspire Private Capital LLC bought a new stake in shares of Merck & Co., Inc. in the fourth quarter worth $55,000. Thor Advisors LLC bought a new stake in shares of Merck & Co., Inc. in the first quarter worth $69,000. Finally, Contravisory Investment Management Inc. increased its stake in shares of Merck & Co., Inc. by 19.7% in the second quarter. Contravisory Investment Management Inc. now owns 858 shares of the company’s stock worth $72,000 after buying an additional 141 shares during the last quarter. Institutional investors own 75.16% of the company’s stock.
MRK has been the subject of a number of research analyst reports. Morgan Stanley lifted their price target on shares of Merck & Co., Inc. from $84.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, June 21st. Atlantic Securities upgraded shares of Merck & Co., Inc. from a “neutral” rating to an “overweight” rating in a research note on Monday, May 13th. They noted that the move was a valuation call. JPMorgan Chase & Co. lifted their price target on shares of Merck & Co., Inc. from $90.00 to $93.00 and gave the stock an “overweight” rating in a research note on Friday, June 14th. Bank of America set a $97.00 price target on shares of Merck & Co., Inc. and gave the stock a “buy” rating in a research note on Thursday, July 11th. Finally, UBS Group lifted their price target on shares of Merck & Co., Inc. from $87.00 to $88.00 and gave the stock a “buy” rating in a research note on Thursday, May 2nd. Three equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Merck & Co., Inc. currently has an average rating of “Buy” and a consensus target price of $90.36.
Merck & Co., Inc. stock traded up $1.10 during mid-day trading on Tuesday, reaching $84.22. The company’s stock had a trading volume of 358,023 shares, compared to its average volume of 10,401,444. The company has a market capitalization of $214.00 billion, a price-to-earnings ratio of 19.33, a price-to-earnings-growth ratio of 1.72 and a beta of 0.56. The firm’s 50 day moving average is $83.27. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 0.82. Merck & Co., Inc. has a twelve month low of $65.68 and a twelve month high of $87.07.
Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, July 30th. The company reported $1.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.14. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 42.84%. The company had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $10.94 billion. During the same quarter in the previous year, the company posted $1.06 earnings per share. The company’s revenue for the quarter was up 12.4% compared to the same quarter last year. As a group, research analysts expect that Merck & Co., Inc. will post 4.91 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Monday, October 7th. Stockholders of record on Monday, September 16th will be issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 2.61%. The ex-dividend date is Friday, September 13th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 50.69%.
About Merck & Co., Inc.
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Recommended Story: Put Option
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.